Table 2.
Comparison of the responder group and the non-responder group of bevacizumab therapy after radiation necrosis
| Variable | Responder (n=36) | Non-responder (n=9) | p-value |
|---|---|---|---|
| Gender | |||
| Male | 18 (50.0) | 5 (55.6) | 1.000 |
| Female | 18 (50.0) | 4 (44.4) | |
| Age at first BEV cycle (years) | 55.3±11.0 | 55.3±7.8 | 0.989 |
| Diagnosis | 0.482 | ||
| Glioma | 15 (41.7) | 5 (55.6) | |
| Grade IV | 3 | 0 | |
| Grade III | 6 | 4 | |
| Grade II | 6 | 1 | |
| Non-glioma | 21 (58.3) | 4 (44.4) | |
| Cerebral metastasis | 12 | 3 | |
| Others | 9 | 1 | |
| Prior brain tumor surgery | 20 (55.6) | 5 (55.6) | 1.000 |
| Prior chemotherapy | 30 (83.3) | 8 (88.9) | 1.000 |
| Prior immunotherapy | 8 (22.2) | 0 (0.0) | 0.179 |
| Early termination of BEV, <4 cycle | 8 (22.2) | 4 (44.4) | 0.219 |
| Latency period from last radiation to diagnosis of radiation necrosis (months) | 13.1±12.8 | 11.6±18.6 | 0.772 |
| Time interval between diagnosis of radiation necrosis and BEV treatment (days) | 89.4±108.6 | 107.3±108.8 | 0.660 |
| Perfusion MRI, rCBV | 0.254 | ||
| No increase | 24 (66.7) | 4 (44.4) | |
| Equivocal | 10 (27.8) | 5 (55.6) | |
| Not checked | 2 (5.6) | 0 (0.0) | |
| DWI/ADC MRI | <0.001* | ||
| No restriction | 27 (75.0) | 0 (0.0) | |
| Restriction | 9 (25.0) | 9 (100.0) | |
| Lesion quotient, T1-CE/T2-FLAIR ratio | 0.31±0.18 | 0.45±0.29 | 0.092 |
Values are presented as mean±standard deviation or number (%).
*
p<0.05.
BEV : bevacizumab, MRI : magnetic resonance imaging, rCBV : relative cerebral blood volume, DWI : diffusion-weighted image, ADC : apparent diffusion coefficient, T1-CE : T1-weighted contrast-enhanced, T2-FLAIR : T2-weighted fluid-attenuated inversion recovery